Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering/FDA Relations Are Priority For Hassan: GMPs, Asmanex On Agenda

Executive Summary

Schering-Plough CEO Fred Hassan hopes his credibility with FDA can help in discussions over the company's GMP work plan and the delayed Asmanex approval
Advertisement

Related Content

Schering GMP Work Plan Is One-Third Complete; Toughest Battles Lie Ahead
Schering Reinvesting In Sales After Cutbacks; “Selective” Support For Zetia
Schering Reinvesting In Sales After Cutbacks; “Selective” Support For Zetia
Schering Reinvesting In Sales After Cutbacks; “Selective” Support For Zetia
Pharmacia II? Schering’s Hassan Brings In Former Colleagues; Zahn Leaves
Schering GMPs Linger: Whistleblower Suit Filed, Consent Decree Extended
Schering OTC Claritin Will Launch In December Without Rx Transition Period
Schering Rebetol Is Only “Medically Necessary” Oral Product In FDA Decree
Schering Rebetol Is Only “Medically Necessary” Oral Product In FDA Decree
Schering-Plough Asmanex
Advertisement
UsernamePublicRestriction

Register

PS042216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel